Glaucoma Surgery Devices Market Global Size, Growth and Covid - 19 Pandemic Impact on Demand 2021-2030

The Global Glaucoma Surgery Devices Market size was valued at USD 786.5 million in 2019 is predicted to garner USD 7.97 billion by 2030, with a CAGR of 23.6% from 2020-2030.

Glaucoma is an ocular disease that affects the optic nerve of the iris diaphragm, and progression of the same results in optic nerve damage or vision loss. In glaucoma, intraocular pressure build-up within the eye due to excessive accumulation of eye-fluid; this may lead to eye-sight damage or blindness. According to the World Health Organization (WHO), glaucoma is the major cause of blindness, specifically in people aged over 60 years, across the globe.

Glaucoma surgery devices play a vital role while operating the patients suffering from glaucoma, hence are adopted on a large scale world-wide. These include various Lasik and non-Lasik implants as well as other such devices that help in reducing the intraocular pressure, thereby leveraging the ocular pressure. In the treatment of glaucoma, optical surgeons either use conventional glaucoma surgeries or minimal invasive glaucoma surgeries.

Request sample copy of this report at:-

https://www.nextmsc.com/Glaucoma-Surgery-Devices-Market/request-sample

Competitive Landscape

Comprehensive competitive analysis and profiles of the major market players such as Ellex Medical Lasers Ltd., Abbott Laboratories, Johnson & Johnson, Alcon, Inc., Topcon Corporation, Glaukos Corporation, New World Medical, Inc., Bausch & Lomb, Inc., Lumenis Ltd., Allergan Plc, and others are provided in the glaucoma surgery devices market report.

An upsurge in R&D activities and advancement in product technologies along with new product launches by the key players, is leading the healthcare infrastructure to new heights, thereby creating lucrative opportunities in the global glaucoma surgery devices market.

For instance, in November 2019, Glaukos Corporation completed its acquisition over Avedro, Inc, resulting into the amalgamation of two highly complementary hybrid pharma & devices organizations. Where Galukos is a pioneer ophthalmic medical-technology & pharmaceutical company in the global glaucoma surgery devices market engrossed in the innovation of novel therapies for treatment of corneal disorders, glaucoma, and retinal diseases; Avedro is a chief commercial-stage ophthalmic medical-technology company engrossed in treating corneal ectatic disorders as well as in improving vision. This acquisition shall reinforce Glaukos’s global commercial sale, market-building, extensive clinical & regulatory infrastructure, and reimbursement expertise, with Averdo’s novel bio-activated pharmaceutical solutions and R&D activities.

Furthermore, in March 2020, Allergan Plc., now acquired by AbbVie Inc., announced that it has received FDA approval for its ‘DURYSTA,’ the bimatoprost implant (10 mcg) for intracameral administration. With this DURYSTA becomes the first-ever ‘intracameral, biodegradable sustained-release implant designated to lower the intraocular pressure in patients suffering from ocular hypertension or open-angle glaucoma. DURYSTA is capable of reducing the intraocular pressure by approximately 30%. Allergan is a leading pharmaceutical company ruling the global glaucoma surgery devices market from more than 70 years. With this milestone Allergen makes a hefty contribution for the glaucoma community, as well as provides a much-needed alternative for patients suffering from topical drops, OAG, OHT, or vision problems.

Access Full Description of this report at:–

https://www.nextmsc.com/report/glaucoma-surgery-devices-market

Top Companies: Ellex Medical Lasers Ltd., Abbott Laboratories, Johnson & Johnson, Alcon, Inc., Topcon Corporation, Glaukos Corporation, New World Medical, Inc., Bausch & Lomb, Inc., Lumenis Ltd., Allergan Plc

Market Segmentations and Scope of the Study:

The glaucoma surgery devices market share has been analyzed based on surgery type, product, end user, and geography.

Based on surgery type, the market is segmented into conventional glaucoma surgeries and minimally invasive glaucoma surgeries. The product segment is further divided into glaucoma drainage devices, glaucoma laser devices, and implants & stents. Based on the end user, the market covers eye hospitals, ophthalmology clinics, and outpatient surgical centers. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis

North America is anticipated to hold the highest glaucoma surgery devices market share throughout the forecast period owing to higher prevalence of glaucoma in this region, increasing adoption of technologically advanced devices for glaucoma surgeries, and better reimbursement facilities.

Asia-Pacific region shall witness an increasing glaucoma surgery devices market size owing to improvement in the healthcare facility and growing awareness about treatment options.

Postal Address:
Phone Number: +1-217-650-7991
E-mail: info@nextmsc.com

About Next Move Strategy Consulting:

Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

For more insights, please visit, https://www.nextmsc.com

This release was published on openPR.